Sarepta Therapeutics Inc. (SRPT)

86.74
1.31 1.49
NASDAQ : Health Technology
Prev Close 88.05
Open 87.24
Day Low/High 86.06 / 88.97
52 Wk Low/High 72.05 / 158.80
Volume 776.31K
Avg Volume 1.71M
Exchange NASDAQ
Shares Outstanding 74.34M
Market Cap 6.37B
EPS -5.50
Div & Yield N.A. (N.A)

Latest News

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Sarepta Therapeutics, Inc. Of Class Action Lawsuit And Upcoming Deadline - SRPT

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Sarepta Therapeutics, Inc. Of Class Action Lawsuit And Upcoming Deadline - SRPT

NEW YORK, Sept. 26, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc.

Sector Liquidations Provide Great Opportunity but Short Term Pain Is Tremendous

Sector Liquidations Provide Great Opportunity but Short Term Pain Is Tremendous

There is no respite today from the poor price action in individual stocks.

Sarepta Therapeutics To Announce 9-Month Functional Results From The SRP-9003 Gene Therapy Trial To Treat Limb-girdle Muscular Dystrophy Type 2E, Or Beta-Sarcoglycanopathy

Sarepta Therapeutics To Announce 9-Month Functional Results From The SRP-9003 Gene Therapy Trial To Treat Limb-girdle Muscular Dystrophy Type 2E, Or Beta-Sarcoglycanopathy

-- Webcast conference call to be held on Friday, Oct. 4, 2019 at 8:00 a.m. Eastern Time --

PayPal, NextEra Energy, Sarepta Therapeutics: 'Mad Money' Lightning Round

PayPal, NextEra Energy, Sarepta Therapeutics: 'Mad Money' Lightning Round

Jim Cramer takes a look at PayPal, NextEra Energy, Sarepta Therapeutics, CEL-SCI, MFA Financial, Fidelity National Services and more.

Time to Take Stock in FAANG: Cramer's 'Mad Money' Recap (Wednesday 9/11/19)

Time to Take Stock in FAANG: Cramer's 'Mad Money' Recap (Wednesday 9/11/19)

Jim Cramer says politicians, media and government agencies may be taking aim at the tech giants, but consumers still love them and their products.

Pilgrim's Pride, Rio Tinto, Sarepta Therapeutics: 'Mad Money' Lightning Round

Pilgrim's Pride, Rio Tinto, Sarepta Therapeutics: 'Mad Money' Lightning Round

Jim Cramer weighs in on Pilgrim's Pride, Rio Tinto, Sarepta Therapeutics, MGP Ingredients, Occidental Petroleum and more.

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Sarepta Therapeutics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Sarepta Therapeutics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sarepta Therapeutics, Inc.

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Sarepta Therapeutics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Sarepta Therapeutics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sarepta Therapeutics, Inc.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm

NEW YORK, Sept. 5, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Sarepta Therapeutics, Inc.

SHAREHOLDER ALERT - Sarepta Therapeutics, Inc. (SRPT) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders Of Class Action And Lead Deadline: October 29, 2019

SHAREHOLDER ALERT - Sarepta Therapeutics, Inc. (SRPT) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders Of Class Action And Lead Deadline: October 29, 2019

NEW YORK, Sept. 4, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Sarepta Therapeutics, Inc.

INVESTOR ALERT: Kirby McInerney LLP Announces An Investigation Of Shareholder Claims Against Sarepta Therapeutics, Inc.

INVESTOR ALERT: Kirby McInerney LLP Announces An Investigation Of Shareholder Claims Against Sarepta Therapeutics, Inc.

--( BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Sarepta Therapeutics, Inc.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

New 52-Week Low Could Prompt More Insider Buying At SRPT

New 52-Week Low Could Prompt More Insider Buying At SRPT

In trading on Thursday, shares of Sarepta Therapeutics Inc touched a new 52-week low of $90.24/share. That's a $75.63 share price drop, or -45.60% decline from the 52-week high of $165.87 set back on 10/01/2018.

Sarepta Craters After FDA Rejection of Muscular Dystrophy Drug

Sarepta Craters After FDA Rejection of Muscular Dystrophy Drug

In its rejection of golodirsen, Sarepta's second treatment for Duchenne muscular dystrophy, the FDA cites concerns over infection risk 'related to intravenous infusion ports and renal toxicity,' the company says.

SRPT: Insiders Vs. Shorts

SRPT: Insiders Vs. Shorts

The most recent short interest data was recently released for the 04/15/2019 settlement date, and Sarepta Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 10.58 "days to cover" versus the median component at 5.30. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc.

Sarepta Therapeutics To Announce Second Quarter 2019 Financial Results And Recent Corporate Developments On August 7, 2019

Sarepta Therapeutics To Announce Second Quarter 2019 Financial Results And Recent Corporate Developments On August 7, 2019

CAMBRIDGE, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc.

Sarepta Therapeutics Looks Ready to Break Out to the Upside

Sarepta Therapeutics Looks Ready to Break Out to the Upside

Here's how to play this stock.

WATCH for Scale: Cramer's 'Mad Money' Recap (Thursday 7/11/19)

WATCH for Scale: Cramer's 'Mad Money' Recap (Thursday 7/11/19)

Jim Cramer highlights companies that can grow so big they make their own destinies: Walmart, Amazon, Target, Costco and Home Depot.

Sarepta Therapeutics Soars as Pfizer's Competing Drug Shows Safety Problems

Sarepta Therapeutics Soars as Pfizer's Competing Drug Shows Safety Problems

An analyst at Baird says a Pfizer gene therapy drug had safety and efficacy issues during a study.

TheStreet Quant Rating: D (Sell)